Top

Published in:

Open Access 01-06-2018 | Leading Article

Drugs in Development for Malaria

Authors: Elizabeth A. Ashley, Aung Pyae Phyo

Published in: Drugs | Issue 9/2018

Abstract

The last two decades have seen a surge in antimalarial drug development with product development partnerships taking a leading role. Resistance of Plasmodium falciparum to the artemisinin derivatives, piperaquine and mefloquine in Southeast Asia means new antimalarials are needed with some urgency. There are at least 13 agents in clinical development. Most of these are blood schizonticides for the treatment of uncomplicated falciparum malaria, under evaluation either singly or as part of two-drug combinations. Leading candidates progressing through the pipeline are artefenomel–ferroquine and lumefantrine-KAF156, both in Phase 2b. Treatment of severe malaria continues to rely on two parenteral drugs with ancient forebears: artesunate and quinine, with sevuparin being evaluated as an adjuvant therapy. Tafenoquine is under review by stringent regulatory authorities for approval as a single-dose treatment for Plasmodium vivax relapse prevention. This represents an advance over standard 14-day primaquine regimens; however, the risk of acute haemolytic anaemia in patients with glucose-6-phosphate dehydrogenase deficiency remains. For disease prevention, several of the newer agents show potential but are unlikely to be recommended for use in the main target groups of pregnant women and young children for some years. Latest predictions are that the malaria burden will continue to be high in the coming decades. This fact, coupled with the repeated loss of antimalarials to resistance, indicates that new antimalarials will be needed for years to come. Failure of the artemisinin-based combinations in Southeast Asia has stimulated a reappraisal of current approaches to combination therapy for malaria with incorporation of three or more drugs in a single treatment under consideration.

World Health Organization. World malaria report. Geneva: World Health Organization; 2017.

World Health Organization. Malaria vaccine: WHO position paper, January 2016—recommendations. Vaccine. 2017. https://doi.org/10.1016/j.vaccine.2016.10.047.CrossRefPubMed

Antimalaria studies on Qinghaosu. Chin Med J. 1979;92(12):811–6.

White NJ, Hien TT, Nosten FH. A brief history of Qinghaosu. Trends Parasitol. 2015;31(12):607–10. https://doi.org/10.1016/j.pt.2015.10.010.PubMedPubMedCentralCrossRef

White N. Antimalarial drug resistance and combination chemotherapy. Philos Trans R Soc Lond Ser B Biol Sci. 1999;354(1384):739–49. https://doi.org/10.1098/rstb.1999.0426.CrossRef

Snow RW, Trape JF, Marsh K. The past, present and future of childhood malaria mortality in Africa. Trends Parasitol. 2001;17(12):593–7.PubMedCrossRef

Fidock DA, Nomura T, Talley AK, Cooper RA, Dzekunov SM, Ferdig MT, et al. Mutations in the P. falciparum digestive vacuole transmembrane protein PfCRT and evidence for their role in chloroquine resistance. Mol Cell. 2000;6(4):861–71.PubMedPubMedCentralCrossRef

Roper C, Pearce R, Nair S, Sharp B, Nosten F, Anderson T. Intercontinental spread of pyrimethamine-resistant malaria. Science (New York, NY). 2004;305(5687):1124. https://doi.org/10.1126/science.1098876.CrossRef

Maxmen A. Busting the billion-dollar myth: how to slash the cost of drug development. Nature. 2016;536(7617):388–90. https://doi.org/10.1038/536388a.PubMedCrossRef

10.

World Health Organization. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.

11.

Premji ZG. Coartem: the journey to the clinic. Malar J. 2009;8(Suppl 1):S3. https://doi.org/10.1186/1475-2875-8-S1-S3.PubMedPubMedCentralCrossRef

12.

Barber BE, Grigg MJ, William T, Yeo TW, Anstey NM. The treatment of Plasmodium knowlesi malaria. Trends Parasitol. 2017;33(3):242–53. https://doi.org/10.1016/j.pt.2016.09.002.PubMedCrossRef

13.

Price RN, von Seidlein L, Valecha N, Nosten F, Baird JK, White NJ. Global extent of chloroquine-resistant Plasmodium vivax: a systematic review and meta-analysis. Lancet Infect Dis. 2014;14(10):982–91.PubMedPubMedCentralCrossRef

14.

Dondorp AM, Fanello CI, Hendriksen IC, Gomes E, Seni A, Chhaganlal KD, et al. Artesunate versus quinine in the treatment of severe falciparum malaria in African children (AQUAMAT): an open-label, randomised trial. Lancet (Lond, Engl). 2010;376(9753):1647–57. https://doi.org/10.1016/s0140-6736(10)61924-1.CrossRef

15.

Dondorp A, Nosten F, Stepniewska K, Day N, White N, South East Asian Quinine Artesunate Malaria Trial Group. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet (Lond, Engl). 2005;366(9487):717–25. https://doi.org/10.1016/s0140-6736(05)67176-0.CrossRef

16.

John CC, Kutamba E, Mugarura K, Opoka RO. Adjunctive therapy for cerebral malaria and other severe forms of Plasmodium falciparum malaria. Expert Rev Anti Infect Ther. 2010;8(9):997–1008. https://doi.org/10.1586/eri.10.90.PubMedPubMedCentralCrossRef

17.

Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359(24):2619–20. https://doi.org/10.1056/NEJMc0805011.PubMedCrossRef

18.

Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361(5):455–67. https://doi.org/10.1056/NEJMoa0808859.PubMedPubMedCentralCrossRef

19.

Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371(5):411–23. https://doi.org/10.1056/NEJMoa1314981.PubMedPubMedCentralCrossRef

20.

Miotto O, Amato R, Ashley EA, MacInnis B, Almagro-Garcia J, Amaratunga C, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet. 2015;47(3):226–34. https://doi.org/10.1038/ng.3189.PubMedPubMedCentralCrossRef

21.

Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505(7481):50–5. https://doi.org/10.1038/nature12876.PubMedCrossRef

22.

Thanh NV, Thuy-Nhien N, Tuyen NT, Tong NT, Nha-Ca NT, Dong LT, et al. Rapid decline in the susceptibility of Plasmodium falciparum to dihydroartemisinin–piperaquine in the south of Vietnam. Malar J. 2017;16(1):27. https://doi.org/10.1186/s12936-017-1680-8.PubMedPubMedCentralCrossRef

23.

Phyo AP, Ashley EA, Anderson TJC, Bozdech Z, Carrara VI, Sriprawat K, et al. Declining efficacy of artemisinin combination therapy against P. Falciparum malaria on the Thai–Myanmar border (2003–2013): the role of parasite genetic factors. Clin Infect Dis Off Publ Infect Dis Soc Am. 2016;63(6):784–91. https://doi.org/10.1093/cid/ciw388.CrossRef

24.

Amato R, Lim P, Miotto O, Amaratunga C, Dek D, Pearson RD, et al. Genetic markers associated with dihydroartemisinin-piperaquine failure in Plasmodium falciparum malaria in Cambodia: a genotype-phenotype association study. Lancet Infect Dis. 2017;17(2):164–73. https://doi.org/10.1016/S1473-3099(16)30409-1.PubMedCrossRef

25.

Witkowski B, Duru V, Khim N, Ross LS, Saintpierre B, Beghain J, et al. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study. Lancet Infect Dis. 2017;17(2):174–83. https://doi.org/10.1016/S1473-3099(16)30415-7.PubMedPubMedCentralCrossRef

26.

Chenet SM, Akinyi Okoth S, Huber CS, Chandrabose J, Lucchi NW, Talundzic E, et al. Independent emergence of the Plasmodium falciparum Kelch propeller domain mutant allele C580Y in Guyana. J Infect Dis. 2016;213(9):1472–5. https://doi.org/10.1093/infdis/jiv752.PubMedCrossRef

27.

Mishra N, Bharti RS, Mallick P, Singh OP, Srivastava B, Rana R, et al. Emerging polymorphisms in falciparum Kelch 13 gene in Northeastern region of India. Malar J. 2016;15(1):583. https://doi.org/10.1186/s12936-016-1636-4.PubMedPubMedCentralCrossRef

28.

Menard D, Khim N, Beghain J, Adegnika AA, Shafiul-Alam M, Amodu O, et al. A worldwide map of Plasmodium falciparum K13-propeller polymorphisms. N Engl J Med. 2016;374(25):2453–64. https://doi.org/10.1056/NEJMoa1513137.PubMedPubMedCentralCrossRef

29.

Burrows JN, van Huijsduijnen RH, Mohrle JJ, Oeuvray C, Wells TN. Designing the next generation of medicines for malaria control and eradication. Malar J. 2013;12:187. https://doi.org/10.1186/1475-2875-12-187.PubMedPubMedCentralCrossRef

30.

Burrows JN, Duparc S, Gutteridge WE, Hooft van Huijsduijnen R, Kaszubska W, Macintyre F, et al. New developments in anti-malarial target candidate and product profiles. Malar J. 2017;16(1):26. https://doi.org/10.1186/s12936-016-1675-x.PubMedPubMedCentralCrossRef

31.

Wells TN, Hooft van Huijsduijnen R, Van Voorhis WC. Malaria medicines: a glass half full? Nat Rev Drug Discov. 2015;14(6):424–42. https://doi.org/10.1038/nrd4573.PubMedCrossRef

32.

Bushell E, Gomes AR, Sanderson T, Anar B, Girling G, Herd C, et al. Functional profiling of a plasmodium genome reveals an abundance of essential genes. Cell. 2017;170(2):260e8–272e8. https://doi.org/10.1016/j.cell.2017.06.030.CrossRef

33.

Hovlid ML, Winzeler EA. Phenotypic screens in antimalarial drug discovery. Trends Parasitol. 2016;32(9):697–707. https://doi.org/10.1016/j.pt.2016.04.014.PubMedPubMedCentralCrossRef

34.

Cowell AN, Istvan ES, Lukens AK, Gomez-Lorenzo MG, Vanaerschot M, Sakata-Kato T, et al. Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics. Science (New York, NY). 2018;359(6372):191–9. https://doi.org/10.1126/science.aan4472.CrossRef

35.

Wells TN, Willis P, Burrows JN, Hooft van Huijsduijnen R. Open data in drug discovery and development: lessons from malaria. Nat Rev Drug Discov. 2016;15(10):661–2. https://doi.org/10.1038/nrd.2016.154.PubMedCrossRef

36.

McCarthy JS, Marquart L, Sekuloski S, Trenholme K, Elliott S, Griffin P, et al. Linking murine and human Plasmodium falciparum challenge models in a translational path for antimalarial drug development. Antimicrob Agents Chemother. 2016;60(6):3669–75. https://doi.org/10.1128/AAC.02883-15.PubMedPubMedCentralCrossRef

37.

Hien TT, White NJ, Thuy-Nhien NT, Hoa NT, Thuan PD, Tarning J, et al. Estimation of the in vivo MIC of cipargamin in uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2017;61(2):e01940-16. https://doi.org/10.1128/aac.01940-16.PubMedPubMedCentralCrossRef

38.

Tagbor H, Cairns M, Bojang K, Coulibaly SO, Kayentao K, Williams J, et al. A non-inferiority, individually randomized trial of intermittent screening and treatment versus intermittent preventive treatment in the control of malaria in pregnancy. PloS One. 2015;10(8):e0132247. https://doi.org/10.1371/journal.pone.0132247.PubMedPubMedCentralCrossRef

39.

Radeva-Petrova D, Kayentao K, ter Kuile FO, Sinclair D, Garner P. Drugs for preventing malaria in pregnant women in endemic areas: any drug regimen versus placebo or no treatment. Cochrane Database Syst Rev. 2014;(10):CD000169. https://doi.org/10.1002/14651858.cd000169.pub3.

40.

Desai M, Gutman J, L’Lanziva A, Otieno K, Juma E, Kariuki S, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin–piperaquine versus intermittent preventive treatment with sulfadoxine–pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet (Lond, Engl). 2015;386(10012):2507–19. https://doi.org/10.1016/s0140-6736(15)00310-4.CrossRef

41.

Permala J, Tarning J, Nosten F, White NJ, Karlsson MO, Bergstrand M. Prediction of improved antimalarial chemoprevention with weekly dosing of dihydroartemisinin–piperaquine. Antimicrob Agents Chemother. 2017;61(5):e02491-16. https://doi.org/10.1128/aac.02491-16.PubMedPubMedCentralCrossRef

42.

Medicines for Malaria Venture. Global portfolio of antimalarial medicines 2017. https://www.mmv.org/research-development/mmv-supported-projects. Accessed 19 Jan 2018.

43.

Clark RL. Improved safety margin for embryotoxicity in rats for the new endoperoxide artefenomel (OZ439) as compared to artesunate. Antimicrob Agents Chemother. 2017. https://doi.org/10.1128/aac.01566-1710.1002/bdr2.1170.PubMedPubMedCentralCrossRef

44.

Charman SA, Arbe-Barnes S, Bathurst IC, Brun R, Campbell M, Charman WN, et al. Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria. Proc Natl Acad Sci USA. 2011;108(11):4400–5. https://doi.org/10.1073/pnas.1015762108.PubMedPubMedCentralCrossRef

45.

Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis. 2015. https://doi.org/10.1016/S1473-3099(15)00320-5.PubMedCrossRef

46.

Held J, Supan C, Salazar CL, Tinto H, Bonkian LN, Nahum A, et al. Ferroquine and artesunate in African adults and children with Plasmodium falciparum malaria: a phase 2, multicentre, randomised, double-blind, dose-ranging, non-inferiority study. Lancet Infect Dis. 2015;15(12):1409–19. https://doi.org/10.1016/S1473-3099(15)00079-1.PubMedCrossRef

47.

Straimer J, Gnadig NF, Stokes BH, Ehrenberger M, Crane AA, Fidock DA. Plasmodium falciparum K13 mutations differentially impact ozonide susceptibility and parasite fitness in vitro. mBio. 2017;8(2):e00172-17. https://doi.org/10.1128/mBio.00172-17.PubMedPubMedCentralCrossRef

48.

Phyo AP, Jittamala P, Nosten FH, Pukrittayakamee S, Imwong M, White NJ, et al. Antimalarial activity of artefenomel (OZ439), a novel synthetic antimalarial endoperoxide, in patients with Plasmodium falciparum and Plasmodium vivax malaria: an open-label phase 2 trial. Lancet Infect Dis. 2016;16(1):61–9. https://doi.org/10.1016/S1473-3099(15)00320-5.PubMedPubMedCentralCrossRef

49.

Macintyre F, Adoke Y, Tiono AB, Duong TT, Mombo-Ngoma G, Bouyou-Akotet M, et al. A randomised, double-blind clinical phase II trial of the efficacy, safety, tolerability and pharmacokinetics of a single dose combination treatment with artefenomel and piperaquine in adults and children with uncomplicated Plasmodium falciparum malaria. BMC Med. 2017;15(1):181.PubMedPubMedCentralCrossRef

50.

White N, Duong TT, Uthaisil C, Nosten F, Phyo AP, Hanboonkunupakarn B, et al. Antimalarial activity of KAF156 in falciparum and vivax malaria. N Engl J Med. 2016;375(12):1152–60.PubMedPubMedCentralCrossRef

51.

Jain JP, Leong FJ, Chen L, Kalluri S, Koradia V, Stein DS, et al. Bioavailability of lumefantrine is significantly enhanced with a novel formulation approach, an outcome from a randomized, open-label pharmacokinetic study in healthy volunteers. Antimicrob Agents Chemother. 2017;61(9):e00868-17. https://doi.org/10.1128/aac.00868-17.PubMedPubMedCentralCrossRef

52.

Ashley EA, Stepniewska K, Lindegardh N, McGready R, Annerberg A, Hutagalung R, et al. Pharmacokinetic study of artemether–lumefantrine given once daily for the treatment of uncomplicated multidrug-resistant falciparum malaria. Trop Med Int Health. 2007;12(2):201–8. https://doi.org/10.1111/j.1365-3156.2006.01785.x.PubMedCrossRef

53.

Denis MB, Tsuyuoka R, Lim P, Lindegardh N, Yi P, Top SN, et al. Efficacy of artemether–lumefantrine for the treatment of uncomplicated falciparum malaria in northwest Cambodia. Trop Med Int Health. 2006;11(12):1800–7. https://doi.org/10.1111/j.1365-3156.2006.01739.x.PubMedCrossRef

54.

Sondo P, Derra K, Diallo Nakanabo S, Tarnagda Z, Kazienga A, Zampa O, et al. Artesunate–amodiaquine and artemether–lumefantrine therapies and selection of Pfcrt and Pfmdr1 Alleles in Nanoro, Burkina Faso. PloS One. 2016;11(3):e0151565. https://doi.org/10.1371/journal.pone.0151565.PubMedPubMedCentralCrossRef

55.

Leong FJ, Jain JP, Feng Y, Goswami B, Stein DS. A phase 1 evaluation of the pharmacokinetic/pharmacodynamic interaction of the anti-malarial agents KAF156 and piperaquine. Malar J. 2018;17(1):7. https://doi.org/10.1186/s12936-017-2162-8.PubMedPubMedCentralCrossRef

56.

Oyakhirome S, Issifou S, Pongratz P, Barondi F, Ramharter M, Kun JF, et al. Randomized controlled trial of fosmidomycin–clindamycin versus sulfadoxine–pyrimethamine in the treatment of Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2007;51(5):1869–71. https://doi.org/10.1128/aac.01448-06.PubMedPubMedCentralCrossRef

57.

Fernandes JF, Lell B, Agnandji ST, Obiang RM, Bassat Q, Kremsner PG, et al. Fosmidomycin as an antimalarial drug: a meta-analysis of clinical trials. Future Microbiol. 2015;10(8):1375–90. https://doi.org/10.1080/21505594.2016.119553710.2217/fmb.15.60.PubMedCrossRef

58.

Borrmann S, Lundgren I, Oyakhirome S, Impouma B, Matsiegui PB, Adegnika AA, et al. Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2006;50(8):2713–8. https://doi.org/10.1128/aac.00392-06.PubMedPubMedCentralCrossRef

59.

Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. Piperaquine: a resurgent antimalarial drug. Drugs. 2005;65(1):75–87.PubMedCrossRef

60.

Mombo-Ngoma G, Remppis J, Sievers M, Zoleko Manego R, Endamne L, Kabwende L, et al. Efficacy and safety of fosmidomycin–piperaquine as non-artemisinin-based combination therapy for uncomplicated falciparum malaria—a single-arm, age-de-escalation proof of concept study in Gabon. Clin Infect Dis Off Publ Infect Dis Soc Am. 2017. https://doi.org/10.1093/cid/cix1122.CrossRef

61.

WorldWide Antimalarial Resistance Network DPSG. The effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin–piperaquine: a pooled analysis of individual patient data. PLoS Med. 2013;10(12):e1001564. https://doi.org/10.1371/journal.pmed.1001564.CrossRef

62.

Murakawa T, Sakamoto H, Fukada S, Konishi T, Nishida M. Pharmacokinetics of fosmidomycin, a new phosphonic acid antibiotic. Antimicrob Agents Chemother. 1982;21(2):224–30.PubMedPubMedCentralCrossRef

63.

White NJ, Pukrittayakamee S, Phyo AP, Rueangweerayut R, Nosten F, Jittamala P, et al. Spiroindolone KAE609 for falciparum and vivax malaria. N Engl J Med. 2014;371(5):403–10. https://doi.org/10.1056/NEJMoa1315860.PubMedPubMedCentralCrossRef

64.

Rottmann M, McNamara C, Yeung BKS, Lee MCS, Zou B, Russell B, et al. Spiroindolones, a potent compound class for the treatment of malaria. Science (New York, NY). 2010;329(5996):1175–80.CrossRef

65.

Stein DS, Jain JP, Kangas M, Lefevre G, Machineni S, Griffin P, et al. Open-label, single-dose, parallel-group study in healthy volunteers to determine the drug-drug interaction potential between KAE609 (cipargamin) and piperaquine. Antimicrob Agents Chemother. 2015;59(6):3493–500. https://doi.org/10.1128/aac.00340-15.PubMedPubMedCentralCrossRef

66.

McCarthy JS, Lotharius J, Ruckle T, Chalon S, Phillips MA, Elliott S, et al. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study. Lancet Infect Dis. 2017;17(6):626–35.PubMedPubMedCentralCrossRef

67.

McCarthy JS, Griffin PM, Sekuloski S, Elliott SM, Marquart L, Klein K, et al. A dose ranging clinical trial to evaluate the pharmacokinetics and pharmacodynamics of the combination of DSM265 and OZ439 in a Plasmodium falciparum induced blood stage malaria system. Am J Trop Med Hyg. 2015;93(4 Supplement):367–8.

68.

Phillips MA, Lotharius J, Marsh K, White J, Dayan A, White KL, et al. A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria. Sci Transl Med. 2015;7(296):aaa6645.CrossRef

69.

Koita OA, Sangare L, Miller HD, Sissako A, Coulibaly M, Thompson TA, et al. AQ-13, an investigational antimalarial, versus artemether plus lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria: a randomised, phase 2, non-inferiority clinical trial. Lancet Infect Dis. 2017;17(12):1266–75. https://doi.org/10.1016/s1473-3099(17)30365-1.PubMedPubMedCentralCrossRef

70.

Mzayek F, Deng H, Mather FJ, Wasilevich EC, Liu H, Hadi CM, et al. Randomized dose-ranging controlled trial of AQ-13, a candidate antimalarial, and chloroquine in healthy volunteers. PLoS Clin Trials. 2007;2(1):e6. https://doi.org/10.1371/journal.pctr.0020006.PubMedPubMedCentralCrossRef

71.

Paquet T, Le Manach C, Cabrera DG, Younis Y, Henrich PP, Abraham TS, et al. Antimalarial efficacy of MMV390048, an inhibitor of Plasmodium phosphatidylinositol 4-kinase. Sci Transl Med. 2017;9(387):eaad9735. https://doi.org/10.1126/scitranslmed.aad9735.PubMedPubMedCentralCrossRef

72.

Baragana B, Hallyburton I, Lee MC, Norcross NR, Grimaldi R, Otto TD, et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature. 2015;522(7556):315–20. https://doi.org/10.1038/nature14451.PubMedPubMedCentralCrossRef

73.

ClinicalTrials.gov. First-in-human trial of single ascending dose, multiple ascending dose and malaria challenge model in healthy subjects NCT03261401. 2017. https://clinicaltrials.gov/ct2/show/study/NCT03261401?view=results. Accessed 14 Jan 2018.

74.

Sulyok M, Ruckle T, Roth A, Murbeth RE, Chalon S, Kerr N, et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect Dis. 2017;17(6):636–44.PubMedPubMedCentralCrossRef

75.

Hoglund RM, Workman L, Edstein MD, Thanh NX, Quang NN, Zongo I, et al. Population pharmacokinetic properties of piperaquine in falciparum malaria: an individual participant data meta-analysis. PLoS Med. 2017;14(1):e1002212. https://doi.org/10.1371/journal.pmed.1002212.PubMedPubMedCentralCrossRef

76.

Barnes KI, Little F, Smith PJ, Evans A, Watkins WM, White NJ. Sulfadoxine–pyrimethamine pharmacokinetics in malaria: pediatric dosing implications. Clin Pharmacol Ther. 2006;80(6):582–96. https://doi.org/10.1016/j.clpt.2006.08.016.PubMedCrossRef

77.

Tarning J, McGready R, Lindegardh N, Ashley EA, Pimanpanarak M, Kamanikom B, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether–lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009;53(9):3837–46. https://doi.org/10.1128/AAC.00195-09.PubMedPubMedCentralCrossRef

78.

GSK. GSK submits US regulatory application for single-dose tafenoquine for Plasmodium vivax malaria. London: GSK; 2017.

79.

Miller AK, Harrell E, Ye L, Baptiste-Brown S, Kleim JP, Ohrt C, et al. Pharmacokinetic interactions and safety evaluations of coadministered tafenoquine and chloroquine in healthy subjects. Br J Clin Pharmacol. 2013;76(6):858–67. https://doi.org/10.1111/bcp.12160.PubMedPubMedCentralCrossRef

80.

Vuong C, Xie LH, Potter BM, Zhang J, Zhang P, Duan D, et al. Differential cytochrome P450 2D metabolism alters tafenoquine pharmacokinetics. Antimicrob Agents Chemother. 2015;59(7):3864–9. https://doi.org/10.1128/aac.00343-15.PubMedPubMedCentralCrossRef

81.

St Jean PL, Xue Z, Carter N, Koh GCKW, Duparc S, Taylor M, et al. Tafenoquine treatment of Plasmodium vivax malaria: suggestive evidence that CYP2D6 reduced metabolism is not associated with relapse in the phase 2b DETECTIVE trial. Malar J. 2016;15(1):97.PubMedPubMedCentralCrossRef

82.

Coulibaly B, Pritsch M, Bountogo M, Meissner PE, Nebie E, Klose C, et al. Efficacy and safety of triple combination therapy with artesunate–amodiaquine–methylene blue for falciparum malaria in children: a randomized controlled trial in Burkina Faso. J Infect Dis. 2015;211(5):689–97. https://doi.org/10.1186/1475-2875-13-41510.1093/infdis/jiu540.PubMedCrossRef

83.

Mbeye NM, ter Kuile FO, Davies MA, Phiri KS, Egger M, Wandeler G, et al. Cotrimoxazole prophylactic treatment prevents malaria in children in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2014;19(9):1057–67. https://doi.org/10.1111/tmi.12352.PubMedPubMedCentralCrossRef

84.

Ouedraogo AL, Bastiaens GJ, Tiono AB, Guelbeogo WM, Kobylinski KC, Ouedraogo A, et al. Efficacy and safety of the mosquitocidal drug ivermectin to prevent malaria transmission after treatment: a double-blind, randomized, clinical trial. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015;60(3):357–65. https://doi.org/10.1093/cid/ciu797.CrossRef

85.

Alout H, Foy BD. Ivermectin: a complimentary weapon against the spread of malaria? Expert Rev Anti Infect Ther. 2017;15(3):231–40. https://doi.org/10.1080/14787210.2017.1271713.PubMedCrossRef

86.

Saiwaew S, Sritabal J, Piaraksa N, Keayarsa S, Ruengweerayut R, Utaisin C, et al. Effects of sevuparin on rosette formation and cytoadherence of Plasmodium falciparum infected erythrocytes. PloS One. 2017;12(3):e0172718. https://doi.org/10.1371/journal.pone.0172718.PubMedPubMedCentralCrossRef

87.

Leitgeb AM, Charunwatthana P, Rueangveerayut R, Uthaisin C, Silamut K, Chotivanich K, et al. Inhibition of merozoite invasion and transient de-sequestration by sevuparin in humans with Plasmodium falciparum malaria. PloS One. 2017;12(12):e0188754. https://doi.org/10.1371/journal.pone.0188754.PubMedPubMedCentralCrossRef

88.

Tekwani BL, Walker LA. 8-Aminoquinolines: future role as antiprotozoal drugs. Curr Opin Infect Dis. 2006;19(6):623–31. https://doi.org/10.1097/QCO.0b013e328010b848.PubMedCrossRef

89.

Fonteilles-Drabek S, Reddy D, Wells TN. Managing intellectual property to develop medicines for the world’s poorest. Nat Rev Drug Discov. 2017;16(4):223–4. https://doi.org/10.1038/nrd.2017.24.PubMedCrossRef

90.

Chavchich M, Birrell GW, Ager AL, MacKenzie DO, Heffernan GD, Schiehser GA, et al. Lead selection of a new aminomethylphenol, JPC-3210, for malaria treatment and prevention. Antimicrob Agents Chemother. 2016;60(5):3115–8. https://doi.org/10.1128/AAC.03066-15.PubMedPubMedCentralCrossRef

91.

Birrell GW, Heffernan GD, Schiehser GA, Anderson J, Ager AL, Morales P, et al. Characterization of the preclinical pharmacology of the new 2-aminomethylphenol, JPC-3210, for malaria treatment and prevention. Antimicrob Agents Chemother. 2018. https://doi.org/10.1128/AAC.01335-17.PubMedCrossRefPubMedCentral

92.

Pegoraro S, Duffey M, Otto TD, Wang Y, Rosemann R, Baumgartner R, et al. SC83288 is a clinical development candidate for the treatment of severe malaria. Nat Commun. 2017;8:14193. https://doi.org/10.1038/ncomms14193.PubMedPubMedCentralCrossRef

93.

Nanayakkara NP, Ager AL Jr, Bartlett MS, Yardley V, Croft SL, Khan IA, et al. Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrob Agents Chemother. 2008;52(6):2130–7. https://doi.org/10.1128/aac.00645-07.PubMedPubMedCentralCrossRef

94.

Deu E. Proteases as antimalarial targets: strategies for genetic, chemical, and therapeutic validation. FEBS J. 2017;284(16):2604–28. https://doi.org/10.1111/febs.14130.PubMedPubMedCentralCrossRef

95.

Pino P, Caldelari R, Mukherjee B, Vahokoski J, Klages N, Maco B, et al. A multistage antimalarial targets the plasmepsins IX and X essential for invasion and egress. Science (New York, NY). 2017;358(6362):522–8. https://doi.org/10.1126/science.aaf8675.CrossRef

96.

Nasamu AS, Glushakova S, Russo I, Vaupel B, Oksman A, Kim AS, et al. Plasmepsins IX and X are essential and druggable mediators of malaria parasite egress and invasion. Science (New York, NY). 2017;358(6362):518–22. https://doi.org/10.1126/science.aan1478.CrossRef

97.

Hodder AN, Sleebs BE, Czabotar PE, Gazdik M, Xu Y, O’Neill MT, et al. Structural basis for plasmepsin V inhibition that blocks export of malaria proteins to human erythrocytes. Nat Struct Mol Biol. 2015;22(8):590–6. https://doi.org/10.1038/nsmb.3061.PubMedCrossRef

98.

Jimenez-Diaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre ME, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci USA. 2014;111(50):E5455–62. https://doi.org/10.1073/pnas.1414221111.PubMedPubMedCentralCrossRef

99.

Gupta P, Mehrotra S, Sharma A, Chugh M, Pandey R, Kaushik A, et al. Exploring heme and hemoglobin binding regions of plasmodium heme detoxification protein for new antimalarial discovery. J Med Chem. 2017;60(20):8298–308. https://doi.org/10.1021/acs.jmedchem.7b00089.PubMedCrossRef

100.

Andrews KT, Tran TN, Fairlie DP. Towards histone deacetylase inhibitors as new antimalarial drugs. Curr Pharm Des. 2012;18(24):3467–79.PubMed

101.

Keough DT, Rejman D, Pohl R, Zbornikova E, Hockova D, Croll T, et al. Design of Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase inhibitors as potential antimalarial therapeutics. ACS Chem Biol. 2017. https://doi.org/10.1021/acschembio.7b00916.PubMedCrossRef

102.

Wright MH, Clough B, Rackham MD, Rangachari K, Brannigan JA, Grainger M, et al. Validation of N-myristoyltransferase as an antimalarial drug target using an integrated chemical biology approach. Nat Chem. 2014;6(2):112–21. https://doi.org/10.1038/nchem.1830.PubMedCrossRef

103.

Kato N, Comer E, Sakata-Kato T, Sharma A, Sharma M, Maetani M, et al. Diversity-oriented synthesis yields novel multistage antimalarial inhibitors. Nature. 2016;538(7625):344–9. https://doi.org/10.1038/nature19804.PubMedPubMedCentralCrossRef

104.

Agarwal D, Gupta RD, Awasthi SK. Are antimalarial hybrid molecules a close reality or a distant dream? Antimicrob Agents Chemother. 2017;61(5):e00249-17. https://doi.org/10.1128/aac.00249-17.PubMedPubMedCentralCrossRef

105.

Reddy PL, Khan SI, Ponnan P, Tripathi M, Rawat DS. Design, synthesis and evaluation of 4-aminoquinoline-purine hybrids as potential antiplasmodial agents. Eur J Med Chem. 2017;126:675–86. https://doi.org/10.1128/aac.01152-1610.1016/j.ejmech.2016.11.057.PubMedCrossRef

106.

Almela MJ, Lozano S, Lelievre J, Colmenarejo G, Coteron JM, Rodrigues J, et al. A new set of chemical starting points with Plasmodium falciparum transmission-blocking potential for antimalarial drug discovery. PloS One. 2015;10(8):e0135139. https://doi.org/10.1371/journal.pone.0135139.PubMedPubMedCentralCrossRef

107.

Hanson KK, Ressurreicao AS, Buchholz K, Prudencio M, Herman-Ornelas JD, Rebelo M, et al. Torins are potent antimalarials that block replenishment of Plasmodium liver stage parasitophorous vacuole membrane proteins. Proc Natl Acad Sci USA. 2013;110(30):E2838–47. https://doi.org/10.1073/pnas.1306097110.PubMedPubMedCentralCrossRef

108.

National Center for Advancing Translational Sciences NIoH. Development of malaria transmission-blocking drugs. 2017. https://ncats.nih.gov/trnd/projects/active/malaria-transmission-blocking-drugs. Accessed 16 Jan 2018.

109.

Delves MJ, Ruecker A, Straschil U, Lelievre J, Marques S, Lopez-Barragan MJ, et al. Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs. Antimicrob Agents Chemother. 2013;57(7):3268–74. https://doi.org/10.1128/aac.00325-13.PubMedPubMedCentralCrossRef

110.

Delves MJ. Plasmodium cell biology should inform strategies used in the development of antimalarial transmission-blocking drugs. Future Med Chem. 2012;4(18):2251–63.PubMedCrossRef

111.

Stone W, Sawa P, Lanke K, Rijpma S, Oriango R, Nyaurah M, et al. A molecular assay to quantify male and female Plasmodium falciparum gametocytes: results from 2 randomized controlled trials using primaquine for gametocyte clearance. J Med Chem. 2017;216(4):457–67. https://doi.org/10.1021/acs.jmedchem.7b0008910.1093/infdis/jix237.CrossRef

112.

Ruecker A, Mathias DK, Straschil U, Churcher TS, Dinglasan RR, Leroy D, et al. A male and female gametocyte functional viability assay to identify biologically relevant malaria transmission-blocking drugs. Antimicrob Agents Chemother. 2014;58(12):7292–302. https://doi.org/10.1128/AAC.03666-14.PubMedPubMedCentralCrossRef

113.

Zeeman AM, van Amsterdam SM, McNamara CW, Voorberg-van der Wel A, Klooster EJ, van den Berg A, et al. KAI407, a potent non-8-aminoquinoline compound that kills Plasmodium cynomolgi early dormant liver stage parasites in vitro. Antimicrob Agents Chemother. 2014;58(3):1586–95. https://doi.org/10.1128/AAC.01927-13.PubMedPubMedCentralCrossRef

114.

Campo B, Vandal O, Wesche DL, Burrows JN. Killing the hypnozoite—drug discovery approaches to prevent relapse in Plasmodium vivax. Pathog Glob Health. 2015;109(3):107–22. https://doi.org/10.1179/2047773215Y.0000000013.PubMedPubMedCentralCrossRef

115.

Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, et al. Artemether–lumefantrine versus dihydroartemisinin–piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PloS One. 2008;3(6):e2390. https://doi.org/10.1371/journal.pone.0002390.PubMedPubMedCentralCrossRef

116.

World Health Organization. Global supply of artemether–lumefantrine before, during, and after the Memorandum of Understanding between WHO and Novartis. Geneva: World Health Organization; 2011.

117.

Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First-time-in-humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg. 1998;58(5):645–9.PubMedCrossRef

118.

Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383(9922):1049–58.PubMedCrossRef

119.

Jefford CW. Synthetic peroxides as potent antimalarials. News and views. Curr Top Med Chem. 2012;12(5):373–99.PubMedCrossRef

120.

Moehrle JJ, Duparc S, Siethoff C, van Giersbergen PL, Craft JC, Arbe-Barnes S, et al. First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials. Br J Clin Pharmacol. 2013;75(2):524–37. https://doi.org/10.1111/j.1365-2125.2012.04368.x.PubMedCrossRef

121.

McCarthy JS, Baker M, O’Rourke P, Marquart L, Griffin P, Hooft van Huijsduijnen R, et al. Efficacy of OZ439 (artefenomel) against early Plasmodium falciparum blood-stage malaria infection in healthy volunteers. J Antimicrob Chemother. 2016;71(9):2620–7. https://doi.org/10.1093/jac/dkw174.PubMedPubMedCentralCrossRef

122.

Mombo-Ngoma G, Supan C, Dal-Bianco MP, Missinou MA, Matsiegui PB, Ospina Salazar CL, et al. Phase I randomized dose-ascending placebo-controlled trials of ferroquine—a candidate anti-malarial drug—in adults with asymptomatic Plasmodium falciparum infection. Malar J. 2011;10:53. https://doi.org/10.1186/1475-2875-10-53.PubMedPubMedCentralCrossRef

123.

Darpo B, Ferber G, Siegl P, Laurijssens B, Macintyre F, Toovey S, et al. Evaluation of the QT effect of a combination of piperaquine and a novel anti-malarial drug candidate OZ439, for the treatment of uncomplicated malaria. Br J Clin Pharmacol. 2015;80(4):706–15. https://doi.org/10.1111/bcp.12680.PubMedPubMedCentralCrossRef

124.

Kuhen KL, Chatterjee AK, Rottmann M, Gagaring K, Borboa R, Buenviaje J, et al. KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission. Antimicrob Agents Chemother. 2014;58(9):5060–7. https://doi.org/10.1128/aac.02727-13.PubMedPubMedCentralCrossRef

125.

Meister S, Plouffe DM, Kuhen KL, Bonamy GMC, Wu T, Barnes SW, et al. Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery. Science (New York, NY). 2011;334(6061):1372–7. https://doi.org/10.1126/science.1211936.CrossRef

126.

Leong FJ, Zhao R, Zeng S, Magnusson B, Diagana TT, Pertel P. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel Imidazolopiperazine KAF156 to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014;58(11):6437–43. https://doi.org/10.1128/AAC.03478-14.PubMedPubMedCentralCrossRef

127.

Spillman NJ, Allen RJ, McNamara CW, Yeung BK, Winzeler EA, Diagana TT, et al. Na(+) regulation in the malaria parasite Plasmodium falciparum involves the cation ATPase PfATP4 and is a target of the spiroindolone antimalarials. Cell Host Microbe. 2013;13(2):227–37. https://doi.org/10.1016/j.chom.2012.12.006.PubMedPubMedCentralCrossRef

128.

Leong FJ, Li R, Jain JP, Lefevre G, Magnusson B, Diagana TT, et al. A first-in-human randomized, double-blind, placebo-controlled, single- and multiple-ascending oral dose study of novel antimalarial Spiroindolone KAE609 (Cipargamin) to assess its safety, tolerability, and pharmacokinetics in healthy adult volunteers. Antimicrob Agents Chemother. 2014;58(10):6209–14. https://doi.org/10.1128/AAC.03393-14.PubMedPubMedCentralCrossRef

129.

Tran HT, White NJ, Nguyen T-NT, Nhu HT, Phung TD, Tarning J, et al. Estimation of the in-vivo minimum inhibitory concentration of cipargamin in uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2016;61:e01940-16.CrossRef

130.

Missinou MA, Borrmann S, Schindler A, Issifou S, Adegnika AA, Matsiegui P-B, et al. Fosmidomycin for malaria. Lancet. 2002;360(9349):1941–2. https://doi.org/10.1016/S0140-6736(02)11860-5.PubMedCrossRef

131.

Guttmann P, Ehrlich P. Ueber die Wirkung des Methylenblau bei Malaria. Berliner Klinische Wochenschrift. 1891;39:953–6.

132.

Bountogo M, Zoungrana A, Coulibaly B, Klose C, Mansmann U, Mockenhaupt FP, et al. Efficacy of methylene blue monotherapy in semi-immune adults with uncomplicated falciparum malaria: a controlled trial in Burkina Faso. Trop Med Int Health. 2010;15(6):713–7.PubMedCrossRef

133.

Zoungrana A, Coulibaly B, Sié A, Walter-Sack I, Mockenhaupt FP, Kouyaté B, et al. Safety and efficacy of methylene blue combined with artesunate or amodiaquine for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. PloS One. 2008;3(2):e1630.PubMedPubMedCentralCrossRef

134.

Paquet T, Chibale K, Street L, Younis Y, Cabrera GD, Le Manach C, et al. Discovery of the 2-aminopyridine MMV390048 as an anti-malarial with the potential to be a component in a single dose cure. Basic Clin Pharmacol Toxicol. 2014;115:226.

135.

Plouffe David M, Wree M, Du Alan Y, Meister S, Li F, Patra K, et al. High-throughput assay and discovery of small molecules that interrupt malaria transmission. Cell Host Microbe. 2016;19(1):114–26. https://doi.org/10.1016/j.chom.2015.12.001.PubMedPubMedCentralCrossRef

136.

Yuthavong Y, Tarnchompoo B, Vilaivan T, Chitnumsub P, Kamchonwongpaisan S, Charman SA, et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci USA. 2012;109(42):16823–8. https://doi.org/10.1073/pnas.1204556109.PubMedPubMedCentralCrossRef

137.

Shafiq N, Rajagopalan S, Kushwaha HN, Mittal N, Chandurkar N, Bhalla A, et al. Single ascending dose safety and pharmacokinetics of CDRI-97/78: first-in-human study of a novel antimalarial drug. Malar Res Treat. 2014;2014:372521. https://doi.org/10.1155/2014/372521.PubMedPubMedCentralCrossRef

138.

Spillman NJ, Kirk K. The malaria parasite cation ATPase PfATP4 and its role in the mechanism of action of a new arsenal of antimalarial drugs. Int J Parasitol Drugs Drug Resist. 2015;5(3):149–62.PubMedPubMedCentralCrossRef

139.

Jiménez-Díaz MB, Ebert D, Salinas Y, Pradhan A, Lehane AM, Myrand-Lapierre M-E, et al. (+)-SJ733, a clinical candidate for malaria that acts through ATP4 to induce rapid host-mediated clearance of Plasmodium. Proc Natl Acad Sci. 2014;111(50):E5455–62.PubMedPubMedCentralCrossRef

140.

Boss C, Aissaoui H, Amaral N, Bauer A, Bazire S, Binkert C, et al. Discovery and characterization of ACT-451840: an antimalarial drug with a novel mechanism of action. ChemMedChem. 2016;11(18):1995–2014. https://doi.org/10.1002/cmdc.201600298.PubMedCrossRef

141.

Bruderer S, Hurst N, de Kanter R, Miraval T, Pfeifer T, Donazzolo Y, et al. First-in-humans study of the safety, tolerability, and pharmacokinetics of ACT-451840, a new chemical entity with antimalarial activity. Antimicrob Agents Chemother. 2015;59(2):935–42. https://doi.org/10.1128/AAC.04125-14.PubMedPubMedCentralCrossRef

142.

Hameed PS, Solapure S, Patil V, Henrich PP, Magistrado PA, Bharath S, et al. Triaminopyrimidine is a fast-killing and long-acting antimalarial clinical candidate. Nat Commun. 2015;6:6715. https://doi.org/10.1038/ncomms7715.CrossRef

143.

Sindhe KMV, Sonoiki E, Guo D, Gut J, Legac J, Tran Y, et al. A new benzoxaborole with an apparent novel mechanism of action against Plasmodium falciparum. In: American Society of tropical medicine and hygiene 65th annual meeting, Atlanta, Georgia. 2016.

144.

McNamara CW, Lee MC, Lim CS, Lim SH, Roland J, Simon O, et al. Targeting Plasmodium PI(4)K to eliminate malaria. Nature. 2013;504(7479):248–53. https://doi.org/10.1038/nature12782.PubMedPubMedCentralCrossRef

145.

Delves M, Plouffe D, Scheurer C, Meister S, Wittlin S, Winzeler EA, et al. The activities of current antimalarial drugs on the life cycle stages of Plasmodium: a comparative study with human and rodent parasites. PLoS Med. 2012;9(2):e1001169. https://doi.org/10.1371/journal.pmed.1001169.PubMedPubMedCentralCrossRef

146.

LaMontagne MP, Blumbergs P, Strube RE. Antimalarials. 14. 5-(aryloxy)-4-methylprimaquine analogues. A highly effective series of blood and tissue schizonticidal agents. J Med Chem. 1982;25(9):1094–7.PubMedCrossRef

147.

Peyton DH. Reversed chloroquine molecules as a strategy to overcome resistance in malaria. Curr Top Med Chem. 2012;12(5):400–7.PubMedPubMedCentralCrossRef

148.

Ubben D, Poll EM. MMV in partnership: the Eurartesim^® experience. Malar J. 2013;12:211. https://doi.org/10.1186/1475-2875-12-211.PubMedPubMedCentralCrossRef

149.

Wells S, Diap G, Kiechel JR. The story of artesunate–mefloquine (ASMQ), innovative partnerships in drug development: case study. Malar J. 2013;12:68. https://doi.org/10.1186/1475-2875-12-68.PubMedPubMedCentralCrossRef

150.

White NJ. Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother. 1997;41(7):1413–22.PubMedPubMedCentralCrossRef

Title: Drugs in Development for Malaria
Authors: Elizabeth A. Ashley
Aung Pyae Phyo
Publication date: 01-06-2018
Publisher: Springer International Publishing
Published in: Drugs / Issue 9/2018
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-018-0911-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Drugs in Development for Malaria

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 9/2018

Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab

Fostamatinib: First Global Approval

Telotristat Ethyl: A Review in Carcinoid Syndrome Diarrhoea

Regorafenib: A Review in Hepatocellular Carcinoma

Targeting EGFR in Lung Cancer: Current Standards and Developments

Correction to: Inhibition of Tissue Factor Pathway Inhibitor (TFPI) as a Treatment for Haemophilia: Rationale with Focus on Concizumab